- Volpara Health Technologies (VHT) makes changes to its leadership team to support its next phase of growth and innovation
- Dr Ralph Highnam will be transitioning to Chief Science and Innovation Officer after 13 years as Group CEO, and will also be stepping down as Director of Volpara
- Teri Thomas, a highly experienced healthcare industry executive with over 20 years’ experience, will be taking over as CEO
- The company did not disclose a timeline but confirmed an orderly transition of responsibilities is underway “and will continue for the next few months”
- Shares in Volpara Health Technologies finished trading yesterday at $0.89 each
Volpara Health Technologies (VHT) has made changes to its leadership team to support its next phase of growth and innovation.
Dr Ralph Highnam will be transitioning to Chief Science and Innovation Officer after 13 years as Group CEO, and will also be stepping down as Director of Volpara.
He will be focusing on leveraging data collated from the company’s analysis of mammogram images and breast composition to develop the next wave of innovative AI enhancements and strengthen Volpara’s portfolio for its extensive customer network.
“Over the last decade, we’ve collated one of the world’s biggest datasets of breast images, a team of bright scientists and a diverse set of industry and academic partners,” Mr Highnam said.
“I’m thrilled to focus my 30 years of experience in healthcare AI toward Volpara’s innovation engine and developing new revenue streams.”
Teri Thomas, a highly experienced healthcare industry executive with over 20 years’ experience, will be taking over as CEO.
Ms Thomas is a registered nurse with a Master of Science degree, which Volpara believes gives her a unique perspective on the intersection of IT, clinical workflow, and patient experience.
Notably, Ms Thomas was a key member of the decision-making team behind Volpara successfully acquiring Harvard spin-out CRA Health in February 2021.
For the next few months, Dr Highnam will continue to host investor presentations and the FY results at the end of May 2022.
Meanwhile, Ms Thomas will be engaging with the sales and marketing teams on the ground in the US as well as meeting with strategic partners and customers.
The company did not disclose a timeline but confirmed an orderly transition of responsibilities is underway “and will continue for the next few months”.
Shares in Volpara Health Technologies finished trading yesterday at $0.89 each.